CAS: 1884712-47-3

CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.

CPI-637 is a potential drug for the treatment of prostate cancer. It is a small molecule that binds to the bromodomain, which is an important cellular protein that regulates transcriptional regulation. Bromodomains are found in many proteins and are known to be involved in many cellular processes and cancers. CPI-637 has been shown to inhibit the expression of genes associated with prostate cancer, HIV infection, and carcinogenesis. This agent does not bind to DNA but binds to histone h3 at a specific site called the response element-binding protein (RBP), which inhibits gene expression by binding to the RBP.

CPI-637